ChemoCentryx Inc represents a strong commitment to scientific innovation, a focus on patient needs, and a dedication to improving the lives of individuals with serious diseases. The company's corporate philosophy revolves around developing novel therapies that target the chemokine system, aiming to address unmet medical needs. With their extensive research and development efforts, ChemoCentryx Inc aims to provide effective treatments in areas such as autoimmune diseases, cancer, and inflammatory disorders. By leveraging their expertise in chemokine biology, they strive to make a positive impact on patient outcomes and contribute to the advancement of healthcare.

ChemoCentryx Inc has a primary presence in various countries and regions. The company operates primarily in the United States, where its headquarters is located. Additionally, ChemoCentryx Inc maintains a strong presence in other parts of North America. It also extends its reach to Europe, including countries like Germany, France, and the United Kingdom. Furthermore, ChemoCentryx Inc has a growing presence in Asia, with a focus on countries such as China and Japan. With its global presence, the company is strategically positioned to serve and expand its customer base in these key markets.

Some significant milestones achieved by ChemoCentryx Inc include the successful completion of multiple clinical trials for their drug candidates, obtaining regulatory approvals for specific treatments, and securing partnerships with other pharmaceutical companies. Additionally, ChemoCentryx Inc has demonstrated positive results in improving patient outcomes and quality of life through their innovative therapies. Notable milestones also include the company's growth and expansion in the pharmaceutical industry, as well as their commitment to advancing research and development efforts in the field of inflammatory and autoimmune diseases.

ChemoCentryx Inc is a biopharmaceutical company with a rich history and background. Founded in 1997, the company is focused on developing innovative solutions for inflammatory and autoimmune diseases. ChemoCentryx has established itself as a leader in the field of chemokine-based therapeutics, leveraging its deep understanding of the chemokine system to discover and develop potent drugs. Over the years, ChemoCentryx has successfully advanced multiple clinical programs, earning recognition for its groundbreaking research in the treatment of various conditions including rare renal diseases and immune-mediated disorders. With a dedicated team of experts and a commitment to improving patient lives, ChemoCentryx continues to make significant contributions to the pharmaceutical industry.

The main competitors of ChemoCentryx Inc in the market include top pharmaceutical companies such as Pfizer, Inc., Novartis AG, and AstraZeneca PLC. These companies specialize in the development and commercialization of innovative drugs and therapies in various therapeutic areas, including immunology and inflammation. ChemoCentryx Inc aims to differentiate itself by focusing on the discovery and development of new medications targeting specific chemokine and chemoattractant receptors. Through its unique approach and collaborative efforts with research partners, ChemoCentryx Inc strives to create effective treatments for patients with rare and serious diseases.

ChemoCentryx Inc is primarily active in the biotechnology industry.

ChemoCentryx Inc is a biopharmaceutical company with a business model that focuses on the discovery, development, and commercialization of orally-administered medicines. The company primarily aims to develop treatments for immune-inflammatory diseases, autoimmune disorders, and cancer. ChemoCentryx Inc is known for its expertise in targeting the chemokine system, a network of molecules involved in various inflammatory processes. Through its research and development efforts, the company strives to deliver innovative therapies that address unmet medical needs and improve patients' lives. ChemoCentryx Inc's business model centers around advancing its pipeline of drug candidates and partnering with pharmaceutical companies to bring these potential treatments to market.

Коефициентът на цена спрямо печалбата (КЦП) на ChemoCentryx е 33,37.

Коефициентът на цена към оборот (KUV) на ChemoCentryx е 8,80.

AlleAktien качественият резултат за ChemoCentryx е 4/10.

очаквана ChemoCentryx оборотът е 412,67 млн. USD.

очаквана ChemoCentryx печалба е 108,81 млн. USD.

ChemoCentryx Inc. is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of autoimmune diseases, inflammation, and cancer. It was founded in California in 1997 and is currently headquartered in San Carlos. The company's business model includes research and development of new drugs, focusing on the identification and study of chemokines involved in various diseases. These chemokines are targeted to achieve therapeutic effects. An example of such a drug is Avacopan, currently in Phase III clinical trials for the treatment of ANCA-associated vasculitis (AAV), a rare autoimmune disease causing inflammation in small blood vessels. Avacopan aims to block the chemokine receptor C5a, which triggers the inflammatory response. ChemoCentryx also forms partnerships with other companies in the pharmaceutical industry to advance its research and development, such as the collaboration with Vifor Pharma for the development and marketing of Avacopan in Europe. In addition to research and development, ChemoCentryx has a clinical development department conducting clinical trials to assess the efficacy and safety of its developed drugs and prepare for FDA or EMA approval. Intellectual property protection is also an important aspect of ChemoCentryx's business model, with several patents on its technologies and drugs to prevent imitation. Overall, ChemoCentryx has a promising business model based on discovering and developing innovative drugs for the treatment of severe diseases. Its goal, supported by a secure financial base and dedicated employees, is to continue developing medications that contribute to improving patients' health.

ChemoCentryx разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за ChemoCentryx в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на ChemoCentryx е US16383L1061.

WKN на ChemoCentryx е A0NBM2.

Тикерът на ChemoCentryx е CCXI.

През последните 12 месеца ChemoCentryx изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква ChemoCentryx да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на ChemoCentryx в момента е .

ChemoCentryx изплаща дивидент на тримесечие. Той се разпределя в месеците .

ChemoCentryx платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

ChemoCentryx се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от ChemoCentryx на 2.12.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 2.12.2024 г..

Последното дивидентно плащане беше извършено на 2.12.2024 г..

През година 2023 ChemoCentryx изплати 0 USD под формата на дивиденти.

Дивидентите от ChemoCentryx се изплащат в USD.